COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
17 hedge funds and large institutions have $633K invested in COSCIENS Biopharma Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.01% less ownership
Funds ownership: 0.07% → 0.05% (-0.01%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
29% less funds holding
Funds holding: 24 → 17 (-7)
47% less capital invested
Capital invested by funds: $1.2M → $633K (-$566K)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$81.9K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$10K |
| 3 |
BlackRock
New York
|
+$4.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$547 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$93K |
| 2 |
Renaissance Technologies
New York
|
-$29.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$3K |
CSCI Hedge Fund Activity: Q1 2020 in Review
17 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2020, worth a combined $633K — down 47% from $1.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CSCI and 1 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $81.9K. The largest seller was Sabby Management, exiting entirely with an estimated $93K sold.
- 17 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2020, down from 24 in Q4 2019.
- Funds reported $633K of COSCIENS Biopharma Inc. Common Stock stock for Q1 2020, down 47% quarter-over-quarter.
- 1 fund opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2020 and 6 closed out, a net change of -5 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2020 was Morgan Stanley, an estimated $81.9K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2020 was Sabby Management, an estimated $93K sold.
Based on aggregated 13F filings for Q1 2020.